Abstract:IMPORTANCE Loss of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression has been reported in several malignant tumors and predicts dismal survival outcomes. In gastric cancer, existing studies on this topic are limited and the association between MGMT and fluorouracil-based adjuvant chemotherapy remains obscure. OBJECTIVE To investigate the postoperative prognostic significance of MGMT in patients with resectable gastric cancer and its responsiveness to fluorouracil-based adjuvant chemotherapy. DESIGN, SETTING, AND PARTICIPANTS This study recruited 445 consecutive patients with resectable gastric cancer who underwent radical gastrectomy between August 1, 2007, and December 30, 2008, at Zhongshan Hospital at Fudan University in Shanghai, China. Patients were randomly divided into a discovery data set (n = 200) and a validation data set (n = 245), and the range of follow-up time was from 2 to 76 months for the discovery group and 2 to 79 months for the validation group. The immunoreactivity for MGMT in cancer cells was reviewed under a light microscope by 2 pathologists who were blinded to the clinicopathological data. The association of MGMT expression with clinicopathological characteristics and measures and prognosis was inspected. Data and specimens were collected from patients from the date of surgery to April 25, 2014. Data analysis took place from May 9, 2016, to July 15, 2016. MAIN OUTCOMES AND MEASURES Estimates of overall survival on the basis of MGMT expression and hazard ratio (HR) for estimates of overall mortality risk. RESULTS Of the 445 patients included in the study, 315 (70.8%) were men, and the mean (SD) age of all patients was 60 (12) years. Positive expression of MGMT indicated better overall survival for patients with stage II or III gastric cancer in both the discovery data set (HR, 0.52; 95% CI, 0.32-0.84; P =.003) and the validation data set (HR, 0.63; 95% CI, 0.43-0.93; P =.01). Multivariate analysis identified MGMT expression and TNM stage as 2 independent prognostic factors for overall survival. In stage II disease, the benefit from fluorouracil-based adjuvant chemotherapy was superior among MGMT-positive patients (HR, 0.35; 95% CI, 0.13-0.95; P =.007 for interaction) compared with MGMT-negative patients. CONCLUSIONS AND RELEVANCE Positive expression of MGMT in gastric cancer was identified as an independent, favorable prognostic factor. Incorporating MGMT expression into the current TNM staging system could lead to better prognostic accuracy. These findings should be confirmed within the framework of randomized clinical trials associated with genomic DNA sequencing studies.

Aberrant DNA Methylation of MGMT and Hmlh1 Genes in Prediction of Gastric Cancer.

Aberrant DNA Methylation of P16, MGMT, and Hmlh1 Genes in Combination with MTHFR C677T Genetic Polymorphism in Gastric Cancer.

O6-methylguanine DNA Methyltransferase is Upregulated in Malignant Transformation of Gastric Epithelial Cells Via Its Gene Promoter DNA Hypomethylation

Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer

Prognostic Significance of Aberrant Gene Methylation in Gastric Cancer.

Diagnostic Accuracy Of Dna Methylation In Detection Of Gastric Cancer: A Meta-Analysis

Combined Detection of Plasma ZIC1, HOXD10 and RUNX3 Methylation is a Promising Strategy for Early Detection of Gastric Cancer and Precancerous Lesions.

Altered 5-Hydroxymethylcytosine Landscape in Primary Gastric Adenocarcinoma

Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis.

Epigenetic Silencing of the MLH1 Promoter in Relation to the Development of Gastric Cancer and Its Use As a Biomarker for Patients with Microsatellite Instability: a Systematic Analysis

Expressions and the Clinical Significance of MGMT, Hmlh1 in Human Gastric Carcinoma

<i>Helicobacter pylori</i> associated aberrant methylation genes in blood leukocyte and gastric mucosa

Amino acid substitution polymorphisms of the DNA repair gene MGMT and the susceptibility to cervical carcinoma.

Aberrant Methylation of Multiple Genes in Gastric Carcinomas

Helicobacter pylori associated aberrant methylation genes in blood leukocyte and gastric mucosa

Expression of Dnmt1, Demethylase, MeCP2 and Methylation of Tumor-Related Genes in Human Gastric Cancer.

[Promoter Region Methylation of DNA Damage Repair Genes in Human Gastric Cancer].

Analysis of DNA Methylation Patterns Associated with the Gastric Cancer Genome.

Hypermethylation Of The Hmlh1 Gene Promoter In Human Gastric Cancers With Microsatellite Instability

Dna Methylation Markers As Predictors Of Initiation And Progression Of Gastric Carcinomas

Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer.